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Abstract
Background: Hepatitis C decreases health related quality of life (HRQL) which is further diminished by antiviral
therapy. HRQL improves after successful treatment. This trial explores the course of and factors associated with
HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study).
Methods: The Short Form (SF)-36 Health Survey was administered at baseline (n = 192) and 24 weeks after the
end of therapy (n = 128).
Results: At baseline HRQL was influenced by age, participating center, severity of liver disease and income.
Exploring the course of HRQL (scores at follow up minus baseline), only the dimension general health increased. In
this dimension patients with a relapse or sustained response differed from non-responders. Men and women
differed in the dimension bodily pain. Treatment schedule did not influence the course of HRQL.
Conclusions: Main determinants of HRQL were severity of liver disease, age, gender, participating center and
response to treatment. Our results do not exclude a more profound negative impact of individualized treatment
compared to standard, possibly caused by higher doses and extended treatment duration in the individualized
group. Antiviral therapy might have a more intense and more prolonged negative impact on females.
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Background
Patients chronically infected with hepatitis C virus
(HCV) have a decreased health related quality of life
(HRQL) compared to the general population [1,2]. The
impact of the disorder is comparable with other stressful
life events and chronic diseases, like diabetes [3]. In part,
the reduction in HRQL is due to the mental compo-
nents of HRQL. With regard to these mental compo-
nents, patients aware of their diagnosis have a more
reduced HRQL than those who are unaware [4].
Furthermore, many HCV patients have a previous or
ongoing addiction and/or psychiatric problems, reflected
in lower HRQL. In addition, patients with hepatitis C
are stigmatized in society and the majority of the popu-
lation of hepatitis C patients has a lower social eco-
nomic status compared to the general population [5].
The reduction of HRQL is probably also due to physi-
cal and psychiatric symptoms as a direct consequence of
this chronic infection and its sequelae (such as cirrho-
sis). The chronic inflammation is believed to signal the
brain and to give rise to neurovegetative symptoms (e.g.
malaise and fatigue) and to amongst others depression
and concentration difficulties [6]. Possibly, also the brain
itself is infected by HCV [7].
Finally, treatment of chronic HCV with (peg)inter-
feron-alpha ((PEG)IFN) and ribavirin (RBV) further
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tion of PEGIFN provided a significant improvement
over standard IFN, with the result that the decrease of
HRQL during treatment with PEGIFN is less than with
standard IFN [8-11]. In case of successful treatment
(obtaining a sustained virological response (SVR)) an
improvement of HRQL-scores is observed [2,8-10].
In the Ditto-study [12] a dynamically individualized
treatment schedule depending on the on-treatment
response was compared to a standard combination ther-
apy with PEGIFN alfa-2a (180 μg qw) plus RBV (1000-
1200 mg qd) for 48 weeks (Figure 1). The primary aim
of the Ditto study was to improve the SVR rate by indi-
vidualizing the treatment schedule, but this could not be
established.
This large scale, multi-centre, international trial,
firstly, provides the opportunity to explore a variety of
factors associated with HRQL in HCV patients at base-
line (treatment naïve; t = 0). Secondly, although type of
treatment, treatment intensity and treatment duration
were heterogeneous this study enabled us to investigate
the course of HRQL during PEGIFN-based treatment
and to add to the existing knowledge on the impact of
cytokine-based antiviral treatment on HRQL. (E.g. do
patients recover 24 weeks after completion of therapy
(follow up) and which factors are associated with the
course of HRQL?)
Methods
Patients
273 patients were included in the study, after informed
consent was obtained, and 270 patients were rando-
mized after 6 weeks of standard treatment. The ethical
review boards of the participating centers approved the
study. After randomization, 134 patients received stan-
dard treatment and 136 patients were treated according
to an individualized treatment schedule depending on
the response at week 4 and 12 of treatment. 216
patients completed the treatment per protocol and 249
patients completed the end of follow up. At t = 0 HRQL
was measured in 192 patients (not every center partici-
pated in the HRQL-analysis) and at follow up (24 weeks
after completion of therapy) in 128 patients. In 120
patients, HRQL could be assessed at both time points.
Study Design
This phase III, open-label, randomized, multicenter trial
was conducted by the DITTO-HCV study group
between February 2001 and November 2003 at 9 centers
in France, Germany, Greece, Israel, Italy, the Nether-
lands, Spain, Sweden, and Switzerland.
Assessments
The Short Form (SF)-36 Health Survey was used to
measure HRQL. The SF-36 generates a profile of HRQL
outcomes by measuring health across eight different
dimensions: physical functioning, role limitation because
of physical health, social functioning, vitality, bodily
pain, mental health, role limitation because of emotional
problems and general health. Responses to each ques-
tion within a dimension are combined to generate a
s c o r ef r o m0t o1 0 0 ,w h e r e1 0 0i n d i c a t e s“good health”.
The eight multi-item subscales were also converted into
a physical component summary scale and a mental com-
ponent summary scale [13]. Demographic (such as age,
gender, and income in Euros) and disease related factors
were assessed before start of treatment. At the moment
the SF-36 was completed at follow up both patients and
the treating physician were unaware of the response to
the treatment because HCV-RNA testing results were
not known yet, however non-responders were aware of
their (positive) HCV-RNA status at relevant time points
during treatment.
Data analysis
Power calculation
The HRQL-analysis was part of the main study which
was powered on significant differences in SVR-rates
between standard and individualized treatment. There-
fore no separate power analysis was performed for this
analysis.
Determinants of HRQL before treatment
To investigate the influence of different characteristics
such as age, grade of fibrosis, and income in Euros, t-
test analysis for dichotomous categorical, univariate ana-
lysis for multicategorical and correlation analysis (Spear-
man) for continuous data were performed (n = 192).
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Figure 1 Treatment allocation of patients with chronic
hepatitis C according to initial virologic response pattern in
the Ditto study. Abbreviations: Ribavirin (RBV), Rapid viral response
(RVR), Slow partial response (SPR), Flat partial response (FPR), null
response (NUR), Standard combination therapy (STD).
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The differences betweenH R Q La tt=0a n df o l l o wu p
were investigated with analysis of variance (ANOVA)
and t-tests for Equality of Means (n = 120).
Explanatory variables on the course of HRQL
a) Effects of response to treatment on the course of
HRQL The course of HRQL was analyzed separately for
patients with SVR, relapse or non-response with t-tests.
Comparison between patients with SVR, with relapse
and non-response was assessed by means of ANOVA.
b) Effects of treatment schedule The mean differences
in quality of life between t = 0 and follow up were com-
pared between patients treated with standard and indivi-
dualized treatment using ANOVA and t-tests for
Equality of Means. Also the mean differences were com-
pared between the groups with RVR (A1, A2 and stan-
dard treatment with RVR) and the groups B2, D and A2
(extended versus shortened therapy, see Figure 1).
c) Effects of patient characteristics on the course of
HRQL With t-test analysis for dichotomous categorical,
univariate analysis for multicategorical and correlation
analysis (Spearman) for continuous data, the influence
on the differences between HRQL at t = 0 and follow
up was determined for the factors age (< 20, 20-29, 30-
39, 40-49, 50-59, 60-69 years), gender, participating cen-
ter, presence of cirrhosis, genotype (1, 4, and 5 versus 2
and 3) and income in Euros.
d) Multivariate analysis For further exploration of the
influence of the different factors mentioned above on
t h ec o u r s eo fH R Q L ,am u l t i v a r i a t ea n a l y s i sw a sp e r -
formed with a correction for age and baseline values of
the SF-36.
Results
Baseline host and virus-related variables were similar in
the standard and the individualized treatment groups
(data not shown).
Determinants of HRQL before treatment
HRQL varied with age, participating center, severity of
liver disease and income in Euros (Table 1). As might
be expected, younger patients had a better performance
compared to older patients, especially on the physical
components of HRQL. Surprisingly, cirrhotic patients
had a better performance than non-cirrhotic patients,
having significantly higher scores on several dimensions
of the SF-36, mostly on mental components. Higher
income in Euros had a weak positive effect on the physi-
cal component summary scale and role limitation
because of physical health scale of HRQL, with a corre-
lation coefficient of 0.30 (p = .003) and 0.23 (p = .002)
respectively. Finally, HRQL differed among the different
participating centers: the mental component summary
scale and the dimensions physical functioning, role
limitation because of physical health, general health,
bodily pain, vitality, social functioning and mental health
were all significantly different between the participating
centers (Figure 2).
Course of HRQL
General health improved significantly at follow up com-
pared to general health at start of treatment (mean
improvement 3.5, p = .04). The subscale physical func-
tioning tended to worsen with a mean decrease of - 3.4
(p = .06) compared to t = 0. Other dimensions did not
change.
Explanatory variables on the differences between HRQL
at baseline and at follow up
a) Effect of response to treatment on course of HRQL
In patients with SVR, as well as with a relapse or non-
response, HRQL did not change compared to t = 0 after
treatment with PEGIFN antiviral therapy, except for an
increase in social functioning in sustained viral respon-
ders (78.8 at baseline, 83.3 at follow up, p = .04).
Among the different groups changes compared to base-
line in the dimensions general health differed signifi-
cantly (p = .02) between patients with a relapse (+ 5.3),
SVR (+ 6.1) and non-response (- 6.3) to treatment.
b) Effect of treatment schedule on course of HRQL
No significant differences were observed in changes in
the different dimensions of the SF-36 between standard
and individualized treatment. A sub-analysis comparing
responders and non-responders separately in standard
and individualized treatme n ts h o w e dn od i f f e r e n c e ,
either. Patients treated for 24 weeks and patients treated
with double dose PEGIFN showed a decline on the
dimensions mental health whereas patients treated for
72 weeks had an increase on this dimension: respectively
- 7.9, - 2.0 and + 18.5.
c) Effects of patient characteristics on course of HRQL
Neither age, genotype nor grade of fibrosis had an influ-
ence on changes in the different dimensions of HRQL.
A significant difference was seen between men and
w o m e ni nt h ed i m e n s i o n sb o d i l yp a i n( m a l e s :+4 . 1 ,
females: - 7.2, p = .02), social functioning (males: + 6.3,
females: - 5.8, p = .008), vitality (males: + 7.2, females: -
2.7, p = .03) and role limitations due to emotional pro-
blems (males: + 9.3, females: - 8.3, p = .05). There was a
weak significant positive correlation between income in
Euros and increase in vitality and mental health between
baseline and follow up: correlation coefficient .30 (p =
.02) for vitality and .21 (p = .03) for mental health. See
Figure 3 and 4.
d) Multivariate analysis
Also in a multivariate analysis gender was a significant
factor on the course of HRQL. All different dimensions,
except for physical component summary scale and
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Subscale t = 0 P-value Course
(follow up - t = 0)
P-value
Age Age category (20-29, 30-39,
40-9, 50-59)
Age category (20-29, 30-39,
40-49,50-59)
Physical functioning 90.6, 93.1, 86.1, 78.1 0.01
Subscale t = 0 P-value Course
(follow up - t = 0)
P-value
Cirrhosis No/Yes No Yes No Yes
Mental component summary scale 44.7 53.7 0.001
General health 61.3 73.5 0.003
Bodily pain 74.2 88.4 0.04
Role limitation because of emotional problems 68.9 88.1 0.05
Mental health 66.4 80.4 0.0004
Subscale t = 0 P-value Course
(follow up - t = 0)
P-value
Income in Euros Subscale SF-36 Correlation coefficient P-value Correlation coefficient P-value
Physical component summary scale 0.30 0.003
Role limitation because of physical health 0.23 0.002
Vitality .30 0.02
Bodily pain 0.18 0.07
Mental health .21 0.03
Subscale t = 0 P-value Course
(Follow up - t = 0)
P-value
Gender (M/F) M F M F
Bodily pain + 4.1 - 7.2 0.02
Social functioning + 6.3 - 5.8 0.008
Vitality + 7.2 - 2.7 0.03
Role limitation because of emotional problems + 9.3 - 8.3 0.05
Results of statistical analysis of the influence of age (ANOVA), presence of cirrhosis (t-test), gender (t-test) and income in Euros (correlation analysis: Spearman) on
Health Related Quality of Life at start of treatment (t = 0) and the course of Health Related Quality of Life (scores at 24 weeks after treatment (Follow up) minus
scores at baseline). Data were shown if relationships were statistically significant.
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Figure 2 Mean scores of the different SF36 dimensions at t = 0
from the participating centers. Barcelona; Spain, Paris; France,
Geneva; Switzerland, Gothenburg; Sweden, Parma; Italy, Rotterdam;
The Netherlands, Rehovot; Israel.
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Figure 3 Mean scores with 95% confidence intervals of the
different dimensions of the SF-36 in men at baseline and at 24
weeks after completion of treatment (follow up).
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and women (Table 2). Response to treatment was again
significantly influencing general health.
In the multivariate analysis, individualized treatment
had a significantly negative influence on the course of
HRQL on the dimensions physical component summary
scale, bodily pain, vitality and social functioning, com-
pared to patients treated with standard treatment (Table
2).
The presence or absence of cirrhosis and grade of
fibrosis did not play a role in the course of HRQL in
this analysis. Also different kind of genotypes (1, 4 and
5 versus 2 and 3) did not influence changes in HRQL.
Discussion
I nt h i ss t u d yw ee x p l o r e dt h ei n f l u e n c eo fP E G I F N -
based antiviral treatment with various regimens and of
patients characteristics on HRQL before as well as at 24
weeks after completion of treatment. Main determinants
of HRQL in this study were the severity of liver disease
(non-cirrhosis vs. cirrhosis), age, gender and participat-
ing center and - to some extent - response to treatment.
With regard to the severity of the liver disease, patients
with cirrhosis did better compared to those without cir-
rhosis. We are unable to explain this difference.
In our study almost all dimensions of the SF-36 did
not change regardless of response, indicative of a satisfy-
ing recovery of patients after cytokine-based therapy.
However, a significant increase was found on the sub-
scale general health despite a therapy-induced worsening
of the subscale physical functioning. This improvement
was seen in patients with both SVR and relapse, whereas
non-responders showed a decrease in general health. In
our study, interestingly the relapsers who were ignorant
of treatment effect when filling in the questionnaire, had
a far more higher score on general health compared to
the non-responders who were aware of their previous
non-response to therapy. This underlines the mental
aspects of the impact on HRQL in this disease [14]. The
observed recovery in HRQL is in line with previous stu-
dies reporting an improvement on (almost) all different
dimensions of the SF-36 after a successful treatment
with PEGIFN and RBV compared to baseline scores
[2,8-10].
The presence of cirrhosis did not influence the course
of HRQL during treatment, but patients with a cirrhosis
had higher scores on some, mostly mental, dimensions
of the SF-36 at t = 0 and at follow up, which is in con-
trast with earlier studies [8,15]. Patients with decompen-
sated cirrhosis were excluded to participate in the study,
but still we cannot explain this difference. Higher age
was associated with a decrease in HRQL, according to
literature data [16].
Men and women differed in the course of HRQL with
an increase on scores for men on several dimensions
and women experiencing a decrease. These differences
between men and women were also significant in a mul-
tivariate analysis for all dimensions except for general
health. In the general population, men report a higher
HRQL [16-18], a finding possibly of relevance for our
findings. But also, therapy with PEGIFN and RBV might
have a more intense and more prolonged impact on
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Figure 4 Mean scores with 95% confidence intervals of the
different dimensions of the SF-36 in females at baseline and at
24 weeks after completion of treatment (follow up).
Table 2 Multivariate analysis
Physical
component
summary
scale
Mental
component
summary
scale
Physical
functioning
Role limitation
because of
physical
health
General
health
Bodily
pain
Vitality Social
functioning
Role limitation
because of
emotional
problems
Mental
health
Gender .043 .050 .030 .006 .009 .001 .024 .023
SVR .047
Standard vs
Individualized
treatment
.031 .019 .027 .031 .075
Multivariate analysis (corrected for baseline value and age) of the influence of gender, response to treatment and kind of therapy on the mean difference
between baseline and follow up (course of Health Related Quality of Life) of the different dimensions of the SF-36.
Only significant p-values are shown in this table.
Abbreviations: Sustained Virological Response (SVR).
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during treatment with PEGIFN and RBV [19]. As ane-
mia plays an important role in HRQL during antiviral
treatment this could be one of the explanations for the
observed difference [20]. With the fixed doses of
PEGIFN women may be treated with higher doses of
PEGIFN per kg, which may contribute to more side-
effects and a lower HRQL during treatment and at 24-
weeks follow-up. To our knowledge, only one study
found sex differences in recovery, with males doing
slightly worse [21].
HRQL at baseline was found to be differing between
the participating centers (in this case different coun-
tries/cultural regions). In the study by Ware et al [9] a
similar observation was made. Although much attention
has been devoted to assure the comparability between
different cultures and languages, this observation sug-
gests that studies from different countries concerning
side effects (for instance decrease of HRQL, but also
psychopathology) should be interpreted with caution
[22,23].
An important limitation of this study is the large
number of variables in relation to the number of partici-
pants and the many different treatment schedules. Also
the relative high number of drop-outs with data of 192
patients at baseline and of 128 patients at follow up
could be of importance, however non-responders or
relapsers were not significantly more non-compliant
compared to responders (data not shown). In retrospect
an additional time point at the end of treatment would
have given more insight.
Conclusion
In conclusion: our findings support the observation, that
in general patients exposed to PEGIFN-based treatment
do recover to their pre-treatment level of baseline, six
months after completion of antiviral therapy or even
surpass that level. This underlines again the safe profile
of this intensive treatment, irrespective of the used
dosage and/or duration in this study. Before treatment
and after treatment with PEGIFN in patients chronically
infected with HCV health related quality of life is mostly
influenced by presence of cirrhosis, age, gender, partici-
pating center (or country) and response to treatment.
Also, awareness of response status to therapy seems
important.
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